Tesamorelin: reference dosing schedule
> Updated:
Human schedule
Tesamorelin is a GHRH analog given by subcutaneous injection (typically into the abdomen). The figures below are a generalized reference drawn from clinical data and protocols, not an individual prescription.
This is a concise reference to regimens described for adults; it is not an individual prescription.
Tesamorelin dosing in the clinical trial was fixed at 2 mg subcutaneously once daily, unlike many research peptides where the schedule is set individually for each protocol.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 1 mg subcutaneously once daily | Starting dose |
| Main regimen | 2 mg subcutaneously once daily | Increase if needed |
| Upper limit | 2 mg per day | Maximum in this schedule |
Background on the molecule, its mechanism and primary sources is covered in the monograph.
Practical dosing and effect details
In a trial by Falutz and colleagues (New England Journal of Medicine, 2007), 412 participants with HIV and abdominal fat accumulation received either 2 mg of tesamorelin subcutaneously once daily or placebo for 26 weeks.
Visceral adipose tissue on CT decreased by 15.2% in the tesamorelin group and increased by 5.0% in the placebo group (p<0.001). Insulin-like growth factor 1 (IGF-1), a biomarker of GHRH-receptor activation, rose 81.0% in the tesamorelin group versus a 5.0% decrease with placebo, tying that specific dose to a measurable biological effect.
The effect held only while dosing continued: researchers assessed outcomes at week 26 of continuous daily administration, not after a short course, so consistency rather than a single dose drove the result. The trial was conducted in adults with HIV-associated lipodystrophy; this is not evidence of an effect in other populations or for other uses. The schedule on this page reproduces the trial dose as reference information, not a medical recommendation.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.